GlassScriptPhysician profile
Brittany L Bouchard
NPI 1316228059
$2,644.00
in general payments reported to CMS, 2019-2025
22 companies · $16.76 in 2025
The $16.76 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $886 · 2023: $1,075 · 2024: $667 · 2025: $16.76.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,730 · Education: $27.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,730.31 |
| Education | $27.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $613.21 | 2022-2024 | |
| Janssen Biotech, INC. | $418.58 | 2022-2024 | Stelara, Simponi, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $208.86 | 2022-2024 | Entyvio, Gattex, Eohilia |
| Braintree Laboratories, INC. | $203.05 | 2022-2024 | Sutab, Suflave |
| Ironwood Pharmaceuticals, INC | $165.51 | 2022-2024 | Linzess |
| Regeneron Healthcare Solutions, INC. | $137.04 | 2022-2024 | Dupixent |
| Ardelyx, INC. | $115.86 | 2022-2023 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $102.29 | 2022-2025 | Xifaxan, Plenvu, Relistor |
| Ferring Pharmaceuticals INC. | $94.40 | 2023-2024 | Rebyota |
| Lilly USA, LLC | $73.57 | 2023-2024 | Omvoh |
| Merck Sharp & Dohme LLC | $68.59 | 2023-2024 | Dificid |
| Celgene Corporation | $67.34 | 2022-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $65.03 | 2022-2024 | Ocaliva |
| Phathom Pharmaceuticals, INC. | $63.59 | 2024 | Voquezna |
| Exact Sciences Corporation | $59.65 | 2023 | Cologuard Collection Kit |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.17 | 2023 | Cyltezo |
| Pfizer INC. | $28.08 | 2022 | |
| Celltrion USA INC. | $27.86 | 2024 | Zymfentra |
| Amgen INC. | $27.18 | 2023 | Amjevita, Avsola |
| Qol Medical, LLC | $24.31 | 2022 | |
| Novo Nordisk INC | $19.88 | 2023 | Wegovy |
| Organon LLC | $17.95 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brittany Bouchard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.